PENILE LENGTH MAINTENANCE POST-PROSTATECTOMY

Principal Investigator: Landon Trost, MD

[Co-Investigator(s)]: Tobias Kohler, MD
Josh Savage, PA-C
Elise Tentis, PA-C
Steve Carlson, APRN, CNP

Funding Sponsor: Mayo Clinic

Study Product: RestoreX®

Document Date: April 5, 2018
## Table of Contents

STUDY SUMMARY ................................................................................................................................. 5

1 INTRODUCTION ...................................................................................................................................... 6

1.1 BACKGROUND .................................................................................................................................. 6
1.2 INVESTIGATIONAL DEVICE ............................................................................................................ 6
1.3 PRELIMINARY DATA ........................................................................................................................ 7
1.4 STUDY RATIONALE AND RISK ANALYSIS (RISKS TO BENEFITS RATIO) .................................... 7
  1.4.1 Study Rationale .......................................................................................................................... 7
  1.4.2 Potential Benefits ....................................................................................................................... 7
1.5 ANTICIPATED DURATION OF THE CLINICAL INVESTIGATION .................................................... 8

2 STUDY OBJECTIVES .......................................................................................................................... 8

2.1 PRIMARY OBJECTIVE ...................................................................................................................... 8
2.2 SECONDARY OBJECTIVE .................................................................................................................. 8

3 STUDY DESIGN .................................................................................................................................... 8

3.1 SUBJECT SELECTION ...................................................................................................................... 9
  3.1.1 Inclusion Criteria ....................................................................................................................... 9
  3.1.2 Exclusion Criteria ..................................................................................................................... 9
3.2 SETTING .......................................................................................................................................... 9
3.3 RECRUITMENT ............................................................................................................................... 9
3.4 CONSENT AND ENROLLMENT ....................................................................................................... 9
3.5 STUDY SCHEMA ............................................................................................................................ 10
3.6 RANDOMIZATION PROTOCOL ...................................................................................................... 11

4 STUDY PROCEDURES ........................................................................................................................ 12

4.1 PRE-OPERATIVE ASSESSMENTS .................................................................................................. 11
4.2 BASELINE ASSESSMENT ............................................................................................................. 11
4.3 6 MONTH VISIT ............................................................................................................................ 12
4.4 9 MONTH VISIT ............................................................................................................................ 12
4.5 ASSESSMENT OF LENGTH ........................................................................................................... 12
4.6 SCHEDULE OF EVENTS ................................................................................................................ 12

5 STATISTICAL PLAN ............................................................................................................................ 13

5.1 DATA HANDLING .......................................................................................................................... 13
5.2 STATISTICAL ANALYSIS ............................................................................................................... 13

6 SAFETY AND ADVERSE EVENTS .................................................................................................... 13

6.1 ADVERSE EVENT REPORTING PERIOD ...................................................................................... 14
6.2 PREEXISTING CONDITION ........................................................................................................... 14
6.3 POST-STUDY ADVERSE EVENT .................................................................................................. 15
6.4 HOSPITALIZATION, PROLONGED HOSPITALIZATION OR SURGERY .......................................... 15
6.5 RECORDING OF ADVERSE EVENTS .......................................................................................... 15
6.6 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS .................... 16
  6.6.1 Sponsor-investigator Reporting: Notifying the Mayo IRB ......................................................... 16
  6.6.2 Stopping Rules ........................................................................................................................ 16
  6.6.3 Medical Monitoring ............................................................................................................... 16

7 DATA HANDLING AND RECORD KEEPING ...................................................................................... 17

7.1 CONFIDENTIALITY ......................................................................................................................... 17
7.2 SOURCE DOCUMENTS .................................................................................................................. 17
7.3 RECORDS RETENTION ............................................................................................................... 17

8 STUDY FINANCES ............................................................................................................................ 18
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event/Adverse Experience</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>PTT</td>
<td>Penile traction therapy</td>
</tr>
<tr>
<td>PD</td>
<td>Peyronie’s Disease</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
</tbody>
</table>
## Study Summary

<table>
<thead>
<tr>
<th>Title</th>
<th>Penile Lengthening Maintenance Post-prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB Protocol Number</td>
<td>18-001013</td>
</tr>
<tr>
<td>Methodology</td>
<td>Controlled randomized study</td>
</tr>
<tr>
<td>Overall Study Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Subject Participation Duration</td>
<td>9 months</td>
</tr>
<tr>
<td>Objectives</td>
<td>Evaluate the efficacy of the RestoreX penile traction device in preventing loss of penile length in men undergoing robotic-assisted prostatectomy</td>
</tr>
<tr>
<td>Number of Subjects</td>
<td>60</td>
</tr>
<tr>
<td>Diagnosis and Main Inclusion Criteria</td>
<td>Men undergoing prostatectomy</td>
</tr>
<tr>
<td>Study Device</td>
<td>RestoreX®, penile traction therapy</td>
</tr>
</tbody>
</table>
| Duration of Exposure | Subjects will use device for 5 months for: 30 minutes, once daily, 5 days a week OR 30 minutes, twice daily, 7 days a week  
After the randomized period, all subjects will be entered into an open-label phase where they may choose to use or not use the device for 3 additional months |
| Reference therapy | During the randomized phase, the use of the device will be compared against a control group using no traction therapy  
In the open label phase, results at the end of 9 months will be compared to those from baseline and at the beginning of the open label phase |
| Statistical Methodology | Stratification of subjects prior to randomization to assure an equal representation based on baseline penile length. Statistical comparisons will be made comparing total penile length prior to and following therapy. Comparisons of subjective questionnaire responses will also be made between groups and at the various time points captured. |
1 Introduction

This document is a protocol for a human research device study. This study will be carried out in accordance with the procedures described in this protocol, applicable United States government regulations and Mayo Clinic policies and procedures.

1.1 Background

The treatment of prostate cancer results in several known sexual dysfunctions, including erectile dysfunction, orgasmic dysfunction, ejaculatory dysfunction, penile curvature (Peyronie’s disease), and reduced penile length. Although all forms of prostate cancer treatment are associated with many of these changes, prostatectomy currently has the most data available on sexual function outcomes. Among the dysfunctions, loss of penile length is often one that results in significant distress and bother to patients. Beyond the esthetic concerns, reduced penile length may lead to inability to participate in sexual intercourse, difficulty with future interventions to restore erectile function (placement of a penile prosthesis), and lead to worsened urinary hygiene (leak urine onto self, leading to yeast infections and other issues).

Penile traction therapy (PTT) is currently the best available treatment to maintain or restore lost penile length due to conditions that reduce length.\(^1\) Prior studies evaluating penile length maintenance post-prostatectomy have utilized a vacuum erection device with varying rates of efficacy. However, to date, no studies have evaluated the benefits of using PTT in this clinical setting. The objective of the current study is to evaluate the efficacy of a novel, Mayo-clinic developed PTT device in maintaining (randomized phase) or restoring (open label phase) reduced penile length.

1.2 Investigational Device

RestoreX is a PTT device developed by PathRight Medical using technology licensed from the Mayo Clinic. The device is classified as class I (orthotic) and does not require clinical trials to prove safety or efficacy. Mayo Clinic is currently conducting a randomized clinical trial to evaluate several clinically relevant factors including safety, comfort, and preference and to provide preliminary data on dosing and efficacy (IRB 17-001283).

The device has two functional aspects. The first is the ability to provide direct traction on the penis. The second is the ability to provide counter-bending forces, to treat conditions such as Peyronie’s disease (bent penis). In the current study, only the direct traction aspects of the device will be investigated.

Men randomized to treatment will be recommended to utilize the device for 5 months for 30 minutes, once daily, 5 days per week or 30 minutes, twice daily, 7 days per week after undergoing a prostatectomy.
After the initial randomized phase, all patients will enter an open-label phase where they may use the device as little or as much as they choose for a period of 6 months.

1.3 Preliminary Data

Currently, there is a small amount of preliminary data available on the RestoreX® instrument. During the developmental phase of the device, a quality improvement project was performed to evaluate the clamping portion. It was determined that the clamp represented the most critical aspect of the device, as this was where the majority of discomfort occurred with other devices. Additionally, the clamp needed to provide sufficient friction to allow adequate traction without having the glans of the penis dislodge from the device.

A total of 15 patients participated in the quality improvement project and had the clamps applied under direct supervision for 30 minutes. After the 30 minutes, all patients reported 0/10 pain, and only minimal transient erythema was documented by the physician. The clamp was again applied, and traction forces were administered to determine if the clamp was able to remain intact despite stretching forces applied. This also resulted in a successful outcome, with all patients able to successfully achieve a minimum required tension of 1 kg, with a 36% safety factor achieved before any discomfort was reported among any patient. During the testing, patients reported improved comfort with the use of a wrap such as gauze or Coban, which permitted additional traction in all patients.

Regarding background data on the RestoreX device, currently, Mayo Clinic is conducting a randomized clinical trial evaluating its role in men with PD (IRB 17-001283). Initial data are expected by the end of 2018.

1.4 Study Rationale and Risk Analysis (Risks to Benefits Ratio)

1.4.1 Study Rationale

PTT has been shown to improve penile length in several clinical scenarios, including following penile surgery, as a primary lengthening therapy, and in men with conditions which shorten the penis such as Peyronie’s disease. To date, no studies have evaluated the role of PTT in maintaining and restoring penile length in men undergoing prostatectomy for prostate cancer. The current study is designed to address this gap in the literature.

1.4.2 Potential Benefits

There are several potential benefits to using PTT following prostatectomy. As loss of penile length results in several issues including loss of sexual function, cosmetic concerns, and difficulty in maintaining hygiene (incontinence resulting in yeast infections), the ability to maintain or restore length post-prostatectomy may mitigate these issues. Additionally, following prostatectomy, an increased percentage of men experience penile curvature (Peyronie’s disease [PD]), which can be both functionally and psychologically distressing.
PTT has previously been demonstrated to limit the extent of penile curvature that men experience among those with early PD, and therefore, the use of PTT early in the post-prostatectomy phase may reduce the likelihood of either developing the condition or in lessening the extent of the condition. It is not expected that the use of PTT will impact (improve or worsen) erectile rigidity post-prostatectomy or impact orgasmic or ejaculatory dysfunctions.

1.5 Anticipated Duration of the Clinical Investigation

The overall study will be scheduled for 3 years, to permit adequate time for enrollment and follow-up. The intervention phase will include 5 months of randomized treatment (for the treatment arm), 3 months of open label treatment (for all arms) and up to 12 months post-prostatectomy follow-up.

2 Study Objectives

2.1 Primary Objective

1. The primary objective is to assess penile length pre and post completion of RestoreX® traction therapy compared to control groups (no treatment) of subjects who have undergone robotic-assisted prostatectomy.

2.2 Secondary Objectives

1. Compare patient compliance with traction device.
2. Compare patient reported satisfaction with use of traction device.
3. Evaluate any adverse events (AEs) with use of RestoreX® for penile lengthening.
4. Compare the rate of Peyronie’s disease development among groups
5. Compare patient satisfaction scores including satisfaction with overall penile length.
6. Evaluate and compare patient erectile function among groups
7. Compare penile length outcomes pre- and post-open phase traction therapy
8. Evaluate the duration of treatment utilized during the open phase of treatment
9. Review associations between pre-surgical factors (demographics, disease-specific factors, and standardized questionnaires) and outcomes

3 Study Design
3.1 Subject Selection

3.1.1 Inclusion Criteria

- Undergoing robotic prostatectomy
- >18 years old
- Seen in the post-prostatectomy rehab clinic

3.1.2 Exclusion Criteria

- Urethral complications from prostatectomy at the time of baseline visit
  - Complications include contrast extravasation, anastomotic dehiscence of vesicourethral anastomosis, need for re-doing of vasicourethral anastomosis intra-operatively

3.2 Setting

The current study will be conducted at the Mayo Clinic in Rochester, MN Department of Urology. All patients will be recruited from the post-prostatectomy rehab clinic.

3.3 Recruitment

Patients attending the post-prostatectomy rehabilitation clinic will be notified of the study and offered participation if meeting inclusion / exclusion criteria. Patients will then be given up to one month post-prostatectomy to decide whether or not they would wish to enroll. Those interested in proceeding with the trial will be invited to meet with a study coordinator. At this time, the details of the study itself will be reviewed with the potential participant. No financial incentives will be provided to participate in the trial; however, participants would be given a RestoreX® device at no charge. Patients will not be charged for any visits related to the study, and no labs or other testing will be obtained which require payment.

3.4 Consent and Enrollment

Patients attending a penile rehabilitation clinic (either prior to or following surgery) will receive a description of the study. Those interested in participating, will be given the opportunity to meet with the study coordinator to further review study details and formal consent. Patients that would like additional time to consider their participation will be given another opportunity to meet with the study coordinator up to one month following the prostatectomy. If the patient expresses interest in participating at any of these times, a formal consent will be reviewed (see Attachment – Consent Form).

At enrollment, all participants will be assigned a study identifier, with a master list maintained in a password protected database (Mayo server) linking the patient to the
identifier. A total of 20 patients will be enrolled into each arm of the study, for a total of 60 patients enrolled overall. It is estimated that 80 patients will need to be screened to enroll the 60 patients.

3.5 Study Schema

Prior to surgery, data will be recorded by the surgeon using the current standard of care questionnaires (EPIC-50, IIEF-15 disease specific variables, and demographics).

Following surgery, patients will be seen in the clinic based on the standard routine clinical practice for their catheter removal (approximately 1-3 weeks post-prostatectomy). At this time, and after the patient has consented, they will undergo initial study penile length assessments (described later in the protocol) and be educated on how to use the device properly by a trained nurse. Patients will then be given a baseline questionnaire to complete. In some cases, patients may not have been provided the IIEF-15 questionnaire prior to surgery. For these patients that have not yet filled out this questionnaire and had their data recorded in their records, they will instead receive the IIEF-15 questionnaire during this baseline visit.

Once consent and study assessments are completed, the patients will be randomized into one of three groups:

1. PTT for 30 min 1x/day, 5 days/week
2. PTT for 30 min 2x/day, 7 days/week
3. Control (no treatment)

Patients in the treatment arm will record a daily journal of their usage of the device. Patients will then begin using the device 4 weeks after surgery as instructed for the times appropriate to their group. This ensures adequate time for the patient to recover from their procedure before beginning to use the device. The study coordinator will call the patient to remind them to begin using the device.

After 5 months of using the device (+1.5 months permitted), patients will return for subsequent assessments (see below) and a follow-up questionnaire. At this time, patients will be encouraged to report any adverse events. They will also be requested to bring their device back to the clinic to review proper usage and any questions on the device. After completion of the subsequent assessments, patients will begin a 3-month, open-label phase of the trial. During this period, the patients will be allowed to use the device for 30 minutes at a time, with a frequency to be determined by the patient.

After completion of the 3-month open-phase portion of the trial, patients will return to the clinic to undergo final assessments, which are identical to the 6-month assessments. Patients will then be encouraged to self-report any additional adverse events (AE’s) that they encounter over the subsequent 6 months.
Since participants are being asked to travel to Mayo Clinic for subsequent assessments, we will provide a remuneration amount of up to $600. The purpose is to assist participants in their travel to and from Mayo Clinic. Those that provide consent will be provided $100 after their baseline assessment. After their second visit, 6 months post-procedure, they will receive $250. After their third visit, 9 month post-procedure, they will receive $250.

3.6 Randomization Protocol

Following enrollment and completion of the initial length assessment, patients will be categorized into the appropriate strata based on their baseline stretched penile length; strata categorized as <10 cm, 10cm-13cm, 13.1cm-16cm, >16cm stretched length. Each stratum will have a separate randomization table provided such that one of three possible outcomes will occur no less frequently than every other case. This is done to better account for baseline variables that may impact outcomes and to assist with matching groupings appropriately.

The explanation of which grouping the patient is assigned will then be reviewed, and if the patient subject is assigned to the treatment group, a RestoreX® device will be provided.

4 Study Procedures

4.1 Pre-Operative Assessments

- Captured as a function of standard care
  - EPIC-50
  - IIEF-15
  - Disease specific variables
  - Demographics
- Participant consented

4.2 Baseline Assessment

- Participant consented (if they were not originally consented at the pre-operative appointment)
- Obtained prior to randomization at time of catheter removal (part of standard care)
- Objective assessments
  - Penile length – measured from pubic symphysis to glanular corona
- Subjective questionnaires (attached)
  - Disease specific history
  - IIEF-15 (for patients who have not completed pre-operatively)
- Device usage diary provided for treatment group
4.3 6 Month Visit

- Penile length assessment
- Questionnaires (attached)
  - 6 month
  - IIEF-15
- Device usage diary retrieved from treatment group
- Device usage diary given to all participants (enter open label phase)

4.4 9 Month Visit

- Penile length assessment
- Questionnaire
  - 9 month
  - IIEF-15
- Retrieve device usage diary

4.5 Assessment of Length
Penile length measurements will be obtained by a member of the clinical team using a measurement from the pubic symphysis to the corona of the glans penis. Measurements will be obtained post-operatively (after catheter removal) and at the 6 and 9 month follow-ups.

See Attachments – Device Usage Diary, Disease Specific History, IIEF-15, Questionnaire 6 Month and 9 Month

4.6 Schedule of Events

Table 1: Schedule of Events

<table>
<thead>
<tr>
<th>Study Activity</th>
<th>Pre-operative</th>
<th>Baseline Assessment (post-operative up to 1 mo)</th>
<th>6 Month</th>
<th>9 Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consent</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPIC-50</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIEF-15</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Disease Specific History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length Assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Page 12 of 18
Dr. Trost
5 Statistical Plan

5.1 Data Handling

All data will be recorded either by the patient themselves or by the provider directly onto printed forms (Attachments). Information will remain de-identified throughout the remainder of the study period and will remain on password protected, Mayo servers.

After completion of the study, de-identified information will be shared with individuals associated with PathRight Medical, Inc. who may assist with portions of the data analysis and/or manuscript drafting. No identifiable information will be sent.

5.2 Statistical Analysis

Analyses will be performed using comparisons within patients of same baseline penile stretch length and between groupings of varying lengths. Comparison of penile length between traction and no traction will be made, as well as reviewing historical records to increase statistical power. Comparison of length from baseline to post-traction for individual participants will also be reviewed.

The data will also be analyzed in three ways: 1- with all patients included, regardless of their compliance to utilize the device for the recommended treatment time, 2- with patients excluded if they failed to achieve 90% compliance with the recommended duration of treatment, 3- with patients excluded if they failed to achieve 80% compliance with the recommended duration of treatment. Comparisons will also be made on other subjective and objective variables obtained including number of adverse events, complications, subjective responses to questionnaires, or other information. All data will be normalized based on pre-operative stretched penile length.

6 Safety and Adverse Events

Definition of Adverse Event
Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO) - any unanticipated problem or adverse event that meets the following three criteria:

Serious: Serious problems or events that result in significant harm, (which may be physical, psychological, financial, social, economic, or legal) or increased risk for the subject or others (including individuals who are not research subjects). These include: (1) death; (2) life threatening adverse experience; (3) hospitalization - inpatient, new, or prolonged; (4) disability/incapacity - persistent or significant; (5) breach of confidentiality and (6) other problems, events, or new information (i.e. publications, interim findings, product labeling change) that in the opinion of the local investigator may adversely affect the rights, safety, or welfare of the subjects or others, or substantially compromise the research data, AND

Unanticipated: (i.e. unexpected) problems or events are those that are not already described as potential risks in the protocol, consent document, not listed in the Investigator’s Brochure, or not part of an underlying disease. A problem or event is "unanticipated" when it was unforeseeable at the time of its occurrence. A problem or event is "unanticipated" when it occurs at an increased frequency or at an increased severity than expected, AND

Related: A problem or event is "related" if it is possibly related to the research procedures.

Adverse Event - an untoward or undesirable experience associated with the use of a medical product (i.e. drug, device, biologic) in a patient or research subject.

Serious Adverse Event - adverse events are classified as serious or non-serious. Serious problems/events can be well defined and include:

- Death
- Life threatening adverse experience
- Hospitalization
- Inpatient, new, or prolonged; disability/incapacity
- And/or per protocol may be problems/events that in the opinion of the sponsor-investigator may have adversely affected the rights, safety, or welfare of the subjects or others, or substantially compromised the research data.

All AEs that do not meet any of the criteria for serious, should be regarded as non-serious AEs.

6.1 Adverse Event Reporting Period

For the current study, the treatment follow-up period is defined as 3 months following the last administration of study treatment.

6.2 Preexisting Condition
A preexisting condition is one that is present at the start of the study. A preexisting condition should be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens during the study period.

At screening, any clinically significant abnormality should be recorded as a preexisting condition. At the end of the study, any new clinically significant findings/abnormalities that meet the definition of an adverse event must also be recorded and documented as an adverse event.

6.3 Post-study Adverse Event

All unresolved AEs will be followed by the study team until the events are resolved, the subject is lost to follow-up, or the AE is otherwise explained. A review of AEs which the subject or subject’s physician believe might reasonably be related to participation in the study will be performed up to 9 months following surgery.

6.4 Hospitalization, Prolonged Hospitalization or Surgery

Any AE related to the study intervention that results in hospitalization or surgery should be documented and reported as a serious AE.

Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an adverse event in the following circumstances:
- Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a preexisting condition. Surgery should not be reported as an outcome of an adverse event if the purpose of the surgery was elective or diagnostic and the outcome was uneventful.

6.5 Recording of Adverse Events

The study team will seek information on adverse events by specific questioning between baseline and the followup visits. Information on all adverse events will be recorded immediately in the adverse event section of the specific questionnaire as well as in an adverse event form (see Attachment – Adverse Event Form).

All adverse events occurring during the study period will be recorded. The clinical course will be followed until resolution, stabilization, or until it has been ultimately determined that the study treatment or participation is not the probable cause. Serious adverse events that are still ongoing at the end of the study period will be followed up, to determine the final outcome. Any serious adverse event that occurs after the study period and is considered to be at least possibly related to the study treatment or study participation will be recorded and reported immediately.
6.6  Reporting of Serious Adverse Events and Unanticipated Problems

When an adverse event has been identified, the study team will take appropriated action necessary to protect the study participant and then complete the Adverse Event Form. The sponsor-investigator will evaluate the event and determine the necessary follow-up and reporting required.

6.6.1  Sponsor-investigator Reporting: Notifying the Mayo IRB

An adverse event form will be completed for any serious adverse event. This will be reported to the Mayo IRB in a de-identified manner.

The study team will report to the Mayo IRB any UPIRTSOs and Non-UPIRTSOs according to the Mayo IRB Policy and Procedures.

Information collected on the adverse event form (and entered into the research database)
• Subject’s ID
• Description of adverse event
• The date the adverse event occurred and resolved (if applicable)
• Intensity
• Outcome
• Action taken to address
• Relationship to study
• Impact on study withdrawal
• Classification as serious or not

The sponsor-investigator will review all adverse event reports to determine if specific reports need to be made to the IRB. The sponsor-investigator will sign and date the adverse event report when it is reviewed. For this protocol, only directly related SAEs/UPIRTSOs will be reported to the IRB.

6.6.2  Stopping Rules

Any serious adverse event which is determined to reasonably be related to the study device by the sponsor-investigator will result in immediate discontinuation of the therapy. If 5 patients develop serious adverse events, the study will be halted with re-review required by the Mayo IRB prior to consideration of study resumption.

6.6.3  Medical Monitoring

Medical monitoring of serious adverse events will be performed by the study investigator on a monthly-basis if serious adverse events have been reported.
7 Data Handling and Record Keeping

7.1 Confidentiality
Information about study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:

- What protected health information (PHI) will be collected from subjects in this study
- Who will have access to that information and why
- Who will use or disclose that information
- The rights of a research subject to revoke their authorization for use of their PHI.

In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (long term survival status that the subject is alive) at the end of their scheduled study period.

7.2 Source Documents

Source data comprise all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents. Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial. When applicable, information recorded on the CRF shall match the Source Data recorded on the Source Documents.

7.3 Records Retention

The sponsor-investigator will maintain records and essential documents related to the conduct of the study. These will include subject case histories and regulatory documents.

The sponsor-investigator will retain the specified records and reports during the study and for the longer of the following:


OR
2. A period of 2 years after the latter of the following two dates: The date on which the investigation is terminated or completed, or the date that the records are no longer required for purposes of supporting a premarket approval application or a notice of completion of a product development protocol.

8 Study Finances

8.1 Funding Source
This study is a Mayo Funded study.

8.2 Conflict of Interest

Dr. Landon Trost is the inventor and developer of the RestoreX® device. His conflict has previously been reviewed with the Mayo Clinic Conflict of Interest Review Board, and following review, it has been determined that Dr. Trost is able to conduct these studies as a Primary Investigator (IRB17-001283).

8.3 Subject Stipends or Payments

Subjects will not receive payment for their participants; however, they will be able to keep the study device following completion of the study.

8.4 Regulatory Information

PathRight Medical has registered the RestoreX® device with the FDA as a Class I device, similar to limb orthotics (see Attachment – RCRI Position Paper). The device is available without a prescription and may be purchased by the general public. As such, clinical studies are not required prior to its routine use, and the current studies are being done as an investigator-initiated project to determine its potential role in length of penile prosthesis inserted.

9 References